A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Financial Summary
| Share Statistics | SDZNY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $39,813.7 | $618.0 | 92% |
|
| Shares Out (Mil) | 438.4 | 44.8 | 87% |
|
| Institutional Ownership | 50.0% | 85.3% | 30% |
|
| Float (Mil) | 414.3 | 47.4 | 83% |
|
| Beta | 0.49 | 0.70 | 28% |
|
| Avg Daily Volume (000s) | 18 | 390 | 20% |
|
| Price Change (52-week) |
51.0% | 68.6% | 80% |
|
| Growth | SDZNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.9% | 6.7% | 27% |
|
| Net Income (5yr) | 14.6% | (1.6%) | 62% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 79% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SDZNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $11,676 | $291 | 86% |
|
| Net Income (TTM) (Mil) | $646 | ($11) | 82% |
|
| EPS (TTM) | $1.490 | ($0.700) | 66% |
|
| Operating Cash Flow (TTM) (Mil) | $1,942 | ($6) | 88% |
|
| Net Cash Flow (TTM) (Mil) | ($139) | $5 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $4,752 | $6 | 85% |
|
| Enterprise Value (Q1) (Mil) | $42,367 | $450 | 90% |
|
| Valuation | SDZNY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SDZNY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.9% | 67.0% | 60% |
|
| Net Margin | 5.5% | (2.3%) | 50% |
|
| ROA | 2.9% | (22.4%) | 61% |
|
| ROE | 7.3% | (20.2%) | 49% |
|
| Liabilities to Assets | 60.5% | 32.2% | 55% |
|
| F-Score | na | 3 | na |
|
Sandoz Group AG did not pass any screens on 8/20/2026.
